eBook: The impact of ADCs on drug discovery
Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes.
They have enjoyed considerable commercial success, particularly in treating cancer, and as a result various different types of bioconjugates are now in development, including bispecific ADCs, dual payload ADCs, antibody-oligo conjugates (AOCs) and radioconjugates (RDCs).
The global antibody-drug conjugates market size was $10.30 billion in 2023 and anticipated to reach around $31.96 billion by 2034, according to predictions from analysts Precedence Research.
This eBook, sponsored by Abzena, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates.
Download this exclusive eBook to learn more about:
- How targeted therapies can reduce cancer side effects
- The challenges in solid tumour targeting with bispecific ADCs
- The future potential for ADCs
- The rise of the bioconjugates
